Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and Docetaxel

Background: HER2-positive advanced breast cancer (ABC) is associated with significant heterogeneity in long-term disease control and survival. Prognostic models for HER2-positive ABC patients considering first-line pertuzumab, trastuzumab, and docetaxel have not been evaluated.Methods: A pre-treatme...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Ashley M. Hopkins, Andrew Rowland, Ross A. McKinnon, Michael J. Sorich
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2019-08-01
Serija:	Frontiers in Oncology
Teme:	anti-HER2 therapies advanced breast cancer prognostic model pertuzumab trastuzumab survival
Online dostop:	https://www.frontiersin.org/article/10.3389/fonc.2019.00789/full
Oznake:	Označite Brez oznak, prvi označite!